|

2-doses Group among 9-14 years Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Shanghai Bovax Biotechnology Co., Ltd.1

Indications

  • CIN11
  • Genital Wart1
  • HPV Infections1
  • CIN31
  • CIN21

Other1 trial

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.